NCT03144804View on ClinicalTrials.gov

A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2017

Primary Completion Date

March 26, 2020

Study Completion Date

September 27, 2022

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Lamivudine

This drug may help prevent the growth and spread of the cancer cells to other parts of the body.

Trial Locations (1)

02114

Massachusetts general Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT03144804 - A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter